Regenxbio Inc (RGNX)

Cash ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash and cash equivalents	US$ in thousands	34,522	96,952	345,209	338,426	69,514
Short-term investments	US$ in thousands	279,578	468,248	504,091	184,074	330,486
Total current liabilities	US$ in thousands	130,272	130,434	130,472	81,447	33,676
Cash ratio		2.41	4.33	6.51	6.42	11.88

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($34,522K + $279,578K) ÷ $130,272K
= 2.41

The cash ratio of Regenxbio Inc has shown a declining trend over the past five years. The ratio has decreased from 9.11 in 2019 to 2.38 in 2023. This indicates that the company's ability to cover its short-term liabilities with its cash and cash equivalents has weakened over time. A lower cash ratio suggests a higher reliance on other sources of liquidity or a decrease in available cash relative to current liabilities. It may be important for stakeholders to monitor this trend closely to assess the company's liquidity position and its ability to meet its short-term obligations.